Aditxt Inc (ADTX) Actualités

Form 8-K - Current report

Form 8-K - Current report

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

  Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive...

KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to...

Form 8-K - Current report

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that...

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potential non-invasive...

Form 8-K - Current report

Form 8-K - Current report

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune...

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

The event will begin today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating...

Form 8-K - Current report

Form 8-K - Current report

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Form 8-K - Current report